Wells Fargo & Company Lowers iTeos Therapeutics (NASDAQ:ITOS) Price Target to $17.00

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) had its target price reduced by investment analysts at Wells Fargo & Company from $19.00 to $17.00 in a research note issued on Thursday, Marketbeat reports. The firm presently has an "overweight" rating on the stock. Wells Fargo & Company's price target would suggest a potential upside of 144.60% from the company's previous close.

A number of other research firms have also issued reports on ITOS. HC Wainwright reiterated a "buy" rating and issued a $46.00 target price on shares of iTeos Therapeutics in a research note on Thursday. Wedbush reiterated an "outperform" rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. Finally, JPMorgan Chase & Co. cut their price objective on shares of iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating for the company in a research report on Thursday.

iTeos Therapeutics Price Performance

ITOS traded down $0.10 during midday trading on Thursday, hitting $6.95. 415,391 shares of the company's stock traded hands, compared to its average volume of 450,404. The company has a market cap of $265.45 million, a PE ratio of -2.21 and a beta of 1.38. The stock's fifty day simple moving average is $7.52 and its 200-day simple moving average is $9.36. iTeos Therapeutics has a one year low of $6.67 and a one year high of $18.75.

Remove Ads

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.13. On average, research analysts expect that iTeos Therapeutics will post -3.49 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Creative Planning increased its holdings in iTeos Therapeutics by 6.5% during the 3rd quarter. Creative Planning now owns 19,636 shares of the company's stock valued at $200,000 after purchasing an additional 1,196 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of iTeos Therapeutics by 12.2% during the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company's stock worth $106,000 after purchasing an additional 1,508 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of iTeos Therapeutics by 16.9% in the fourth quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock valued at $128,000 after buying an additional 2,402 shares in the last quarter. Point72 DIFC Ltd bought a new position in shares of iTeos Therapeutics in the third quarter valued at about $31,000. Finally, Virtus ETF Advisers LLC lifted its position in iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock worth $69,000 after buying an additional 3,293 shares in the last quarter. Institutional investors own 97.16% of the company's stock.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.